Merck’s Experimental Drug Reduces Allergic Reaction to Ragweed

by Kathy Jones on  March 6, 2012 at 9:33 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

Pharmaceutical giant Merck has announced that it will be filing a marketing approval with the US Food and Drug Administration next year for its experimental drug that reduces the allergic reactions to ragweed and grass.
 Merck’s Experimental Drug Reduces Allergic Reaction to Ragweed
Merck’s Experimental Drug Reduces Allergic Reaction to Ragweed

Merck said that the results of its clinical trials revealed that those who took the drugs showed up to 27 percent reduction in the allergy symptoms. More than 560 adults between 18 and 50 years of age took part in the study with the participants given either two different doses of the drug or a placebo.

According to Merck, those who took a lower dose of the drug had 21 percent reduction in symptoms and 34 percent reduction in taking medication compared to the placebo group while those who took the higher dose had 27 percent reduction in symptoms and 45 percent reduction in medication.

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Allergy Drug Toxicity Signature Drug Toxicity Dealing with Pollen Allergy Anaphylaxis Aspergillosis Sulphonamide Allergy Erythema 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive